Baillie Gifford & Co. raised its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 1.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 872,225 shares of the biopharmaceutical company’s stock after purchasing an additional 9,510 shares during the quarter. Baillie Gifford & Co.’s holdings in Agios Pharmaceuticals were worth $58,822,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Quantamental Technologies LLC acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at $28,000. Advisor Group Inc. increased its stake in Agios Pharmaceuticals by 33.1% in the fourth quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 297 shares during the period. ETF Managers Group LLC increased its stake in Agios Pharmaceuticals by 15.7% in the fourth quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 216 shares during the period. S&CO Inc. acquired a new position in Agios Pharmaceuticals in the first quarter valued at $229,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Agios Pharmaceuticals by 14.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 430 shares during the period. Institutional investors own 98.27% of the company’s stock.
A number of research analysts have commented on AGIO shares. ValuEngine lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Leerink Swann upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Friday, February 15th. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Finally, Piper Jaffray Companies lowered their target price on shares of Agios Pharmaceuticals to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 14th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $97.86.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.75) by $0.16. The business had revenue of $30.20 million for the quarter, compared to the consensus estimate of $22.69 million. Agios Pharmaceuticals had a negative net margin of 366.61% and a negative return on equity of 44.13%. The business’s quarterly revenue was up 243.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.63) earnings per share. As a group, sell-side analysts expect that Agios Pharmaceuticals Inc will post -6.73 EPS for the current year.
In other news, insider Christopher Bowden sold 10,000 shares of Agios Pharmaceuticals stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $64.16, for a total value of $641,600.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Scott Biller sold 9,000 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $65.00, for a total transaction of $585,000.00. Following the completion of the sale, the insider now directly owns 28,277 shares in the company, valued at approximately $1,838,005. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,000 shares of company stock worth $2,765,530. Insiders own 3.16% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2019/05/03/baillie-gifford-co-acquires-9510-shares-of-agios-pharmaceuticals-inc-agio.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.
Featured Story: Market Capitalization in the Stock Market
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.